Investigational drugs in recent clinical trials for treatment-resistant depression

References

• McIntyre RS, Filteau M-J, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1–7.
   PubMed Web of Science ®Google Scholar
• Holtzmann J, Richieri R, Saba G, et al. How to define treatment-resistant depression? Presse Méd. 2016;45:323–328.
   PubMed Web of Science ®Google Scholar
• Trevino K, McClintock SM, McDonald Fischer N, et al. Defining treatment-resistant depression: a comprehensive review of the literature. Ann Clin Psychiatry. 2014;26:222–232.
   PubMed Web of Science ®Google Scholar
• Gaynes B. Assessing the risk factors for difficult-to-treat depression and treatment-resistant depression. J Clin Psychiatry. 2016;77(Suppl 1):4–8.
   PubMed Web of Science ®Google Scholar
• Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369–388.
   PubMed Web of Science ®Google Scholar
• Thase ME. Treatment-resistant depression: prevalence, risk factors, and treatment strategies. J Clin Psychiatry. 2011;72:e18.
   PubMedGoogle Scholar
• Ionescu DF, Rosenbaum JF, Alpert JE. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues Clin Neurosci. 2015;17:111–126.
   PubMed Web of Science ®Google Scholar
• Ferrari AJ, Somerville AJ, Baxter AJ, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med. 2013;43:471–481.
   PubMed Web of Science ®Google Scholar
• Holtzheimer PE, Mayberg HS. Stuck in a rut: rethinking depression and its treatment. Trends Neurosci. 2011;34:1–9.
   PubMed Web of Science ®Google Scholar
• Coplan JD, Gopinath S, Abdallah CG, et al. A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy. Front Behav Neurosci. 2014;8:189.
   PubMed Web of Science ®Google Scholar
• Knochel C, Alves G, Friedrichs B, et al. Treatment-resistant late-life depression: challenges and perspectives. Curr Neuropharmacol. 2015;13:577–591.
   PubMed Web of Science ®Google Scholar
• Lang UE, Borgwardt S. Molecular mechanisms of depression: perspectives on new treatment strategies. Cell Physiol Biochem. 2013;31:761–777.
   PubMed Web of Science ®Google Scholar
• Jaso BA, Niciu MJ, Iadarola ND, et al. Therapeutic modulation of glutamate receptors in major depressive disorder. Curr Neuropharmacol. 2016;15:57–70.
   Web of Science ®Google Scholar
• Kim YK, Na KS. Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry. 2016;70:117–126.
   PubMed Web of Science ®Google Scholar
• FDA. Food and Drug Administration. Drugs@FDA. Symbyax. Label information 2014 [cited 2016 Jun 8]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021520s034lbl.pdf].
   Google Scholar
• Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med. 2010;122:39–48.
   PubMed Web of Science ®Google Scholar
• Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2015;69:978–997.
   PubMed Web of Science ®Google Scholar
• Cha DS, McIntyre RS. Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin Pharmacother. 2012;13:1587–1598.
   PubMed Web of Science ®Google Scholar
• Nelson JC, Baumann P, Delucchi K, et al. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord. 2014;168:269–275.
   PubMed Web of Science ®Google Scholar
• Cooper-Kazaz R, Lerer B. Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol. 2008;11:685–699.
   PubMed Web of Science ®Google Scholar
• Appelberg BG, Syvalahti EK, Koskinen TE, et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry. 2001;62:448–452.
   PubMed Web of Science ®Google Scholar
• Tallon D, Wiles N, Campbell J, et al. Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial. Trials. 2016;17:66.
   PubMed Web of Science ®Google Scholar
• Bodkin JA, Lasser RA, Wines JD Jr., et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry. 1997;58:137–145.
   PubMed Web of Science ®Google Scholar
• Howland RH. Sequenced treatment alternatives to relieve depression (STAR*D). Part 2: study outcomes. J Psychosoc Nurs Ment Health Serv. 2008;46:21–24.
   Web of Science ®Google Scholar
• Lomas J, Llewellyn A, Soares M, et al. The clinical and cost effectiveness of vortioxetine for the treatment of a major depressive episode in patients with failed prior antidepressant therapy: a critique of the evidence. Pharmacoeconomics. 2016;34:901–912.
   PubMed Web of Science ®Google Scholar
• Abel A, Hayes AM, Henley W, et al. Sudden gains in cognitive-behavior therapy for treatment-resistant depression: processes of change. J Consult Clin Psychol. 2016;84:726–737.
   PubMed Web of Science ®Google Scholar
• Block SG, Nemeroff CB. Emerging antidepressants to treat major depressive disorder. Asian J Psychiatr. 2014;12:7–16.
   PubMedGoogle Scholar
• Wijesinghe R. Emerging therapies for treatment resistant depression. Mental Health Clinician. 2014;4:226–230.
   Google Scholar
• Health Quality O. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials. Ont Health Technol Assess Ser. 2016;16:1–66.
   Google Scholar
• Berry SM, Broglio K, Bunker M, et al. A patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression. Med Devices (Auckl). 2013;6:17–35.
   PubMedGoogle Scholar
• Garay RP, Citrome L, Samalin L, et al. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opin Pharmacother. 2016;17:921–936.
   PubMed Web of Science ®Google Scholar
• Garay RP, Citrome L, Grossberg GT, et al. Investigational drugs for treating agitation in persons with dementia. Expert Opin Investig Drugs. 2016;25:973–983.
   PubMed Web of Science ®Google Scholar
• Garay RP, Bourin M, De Paillette E, et al. Potential serotonergic agents for the treatment of schizophrenia. Expert Opin Investig Drugs. 2016;25:159–170.
   PubMed Web of Science ®Google Scholar
• EMA. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of depression 2013 [cited 2016 Jun 8]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500143770.pdf].
   Google Scholar
• Naughton M, Clarke G, O′Leary OF, et al. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord. 2014;156:24–35.
   PubMed Web of Science ®Google Scholar
• DeWilde KE, Levitch CF, Murrough JW, et al. The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015;1345:47–58.
   PubMed Web of Science ®Google Scholar
• Murrough JW. Ketamine as a novel antidepressant: from synapse to behavior. Clin Pharmacol Ther. 2012;91:303–309.
   PubMed Web of Science ®Google Scholar
• Singh JB, Fedgchin M, Daly EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173(8):816–826.
   Web of Science ®Google Scholar
• Zarate CA Jr., Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–864.
   PubMed Web of Science ®Google Scholar
• Kurdi MS, Theerth KA, Deva RS. Ketamine: current applications in anesthesia, pain, and critical care. Anesth Essays Res. 2014;8:283–290.
   PubMedGoogle Scholar
• Loo CD. Is ketamine ready to be used clinically for the treatment of depression? Med J Aust. 2015;203:425–426.
   PubMed Web of Science ®Google Scholar
• McGirr A, Berlim MT, Bond DJ, et al. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015;45:693–704.
   PubMed Web of Science ®Google Scholar
• Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 1992;260:1209–1213.
   PubMed Web of Science ®Google Scholar
• Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg. 1998;87:1186–1193.
   PubMed Web of Science ®Google Scholar
• Brunner E, Tohen M, Osuntokun O, et al. Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. Neuropsychopharmacology. 2014;39:2549–2559.
   PubMed Web of Science ®Google Scholar
• Bobo WV, Voort JL, Croarkin PE, et al. Ketamine for treatment-resistant unipolar and bipolar major depression: critical review and implications for clinical practice. Depress Anxiety. 2016;33:698–710.
   PubMed Web of Science ®Google Scholar
• Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry. 2002;7:837–844.
   PubMed Web of Science ®Google Scholar
• Pochwat B, Palucha-Poniewiera A, Szewczyk B, et al. NMDA antagonists under investigation for the treatment of major depressive disorder. Expert Opin Investig Drugs. 2014;23:1181–1192.
   PubMed Web of Science ®Google Scholar
• Newport DJ, Carpenter LL, McDonald WM, et al. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry. 2015;172:950–966.
   PubMed Web of Science ®Google Scholar
• Li CT, Chen MH, Lin WC, et al. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: a randomized controlled study. Hum Brain Mapp. 2016;37:1080–1090.
   PubMed Web of Science ®Google Scholar
• Ionescu DF, Swee MB, Pavone KJ, et al. Rapid and sustained reductions in current suicidal ideation following repeated doses of intravenous ketamine: secondary analysis of an open-label study. J Clin Psychiatry. 2016;77:e719–25.
   PubMed Web of Science ®Google Scholar
• Sos P, Klirova M, Novak T, et al. Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett. 2013;34:287–293.
   PubMed Web of Science ®Google Scholar
• Zhang MW, Harris KM, Ho RC. Is Off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications. BMC Med Ethics. 2016;17:4.
   PubMed Web of Science ®Google Scholar
• Irwin SA, Iglewicz A, Nelesen RA, et al. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. J Palliat Med. 2013;16:958–965.
   PubMed Web of Science ®Google Scholar
• Domani Y, Bleich-Cohen M, Stoppelman N, et al. Oral ketamine for treatment resistant major depression – a double blind randomized controlled trial. European Psychiatry (24th European Congress of Psychiatry). 2016;33S:S523.
   Google Scholar
• Zarate C, Duman RS, Liu G, et al. New paradigms for treatment-resistant depression. Ann N Y Acad Sci. 2013;1292:21–31.
   PubMed Web of Science ®Google Scholar
• Zanos P, Moaddel R, Morris PJ, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481–486.
   PubMed Web of Science ®Google Scholar
• Deakin JF, Lees J, McKie S, et al. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry. 2008;65:154–164.
   PubMed Web of Science ®Google Scholar
• Hashimoto K. R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity. Psychological Med. 2016;46:2449–2451.
   PubMed Web of Science ®Google Scholar
• Domino EF. Taming the ketamine tiger. 1965. Anesthesiology. 2010;113:678–684.
   PubMed Web of Science ®Google Scholar
• Daly EJ, Singh JB, Fedgchin M, et al. Intranasal esketamine in treatment-resistant depression, a dose response study – double-blind and open-label extension data. 54th Annual Meeting of the American College of Neuropsychopharmacology 2015;(ACNP), 2015 December 6th-10th. Hollywood, Florida, USA:74
   Google Scholar
• Zhang J, Li S, Hashimoto K. R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav. 2014;116:137–141.
   PubMed Web of Science ®Google Scholar
• Canuso CM, Singh J, Fedgchin M, et al. PeRSEVERe: a study of esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in patients assessed to be at imminent risk for suicide. Presented at American Society of Clinical Psychopharmacology 2016;(ASCP), May 30-June 3, 2016, Scottsdale, AZ, USA:
   Google Scholar
• Singh JB, Fedgchin M, Daly E, et al. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry. 2015;173:816–826.
   Google Scholar
• Jarventausta K, Chrapek W, Kampman O, et al. Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study. J Ect. 2013;29:158–161.
   PubMed Web of Science ®Google Scholar
• FDA. Food and Drug Administration. Drugs@FDA. Buprenorphine. Drug approval package. 2002 [cited 2016 Jun 8]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-732_20-733_Subutex.cfm].
   Google Scholar
• Karp JF, Butters MA, Begley AE, et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75:e785–93.
   PubMed Web of Science ®Google Scholar
• Sher L. Buprenorphine and the treatment of depression, anxiety, non-suicidal self-injury, and suicidality. Acta Psychiatr Scand. 2016;134:84–85.
   PubMed Web of Science ®Google Scholar
• Bodkin JA, Zornberg GL, Lukas SE, et al. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15:49–57.
   PubMed Web of Science ®Google Scholar
• Norelli LJ, Smith HS, Sher L, et al. Buprenorphine in the treatment of non-suicidal self-injury: a case series and discussion of the literature. Int J Adolesc Med Health. 2013;25:323–330.
   PubMedGoogle Scholar
• Ehrich E, Turncliff R, Du Y, et al. Evaluation of opioid modulation in major depressive disorder. Neuropsychopharmacol. 2015;40:1448–1455.
   PubMed Web of Science ®Google Scholar
• Fava M, Memisoglu A, Thase ME, et al. Opioid modulation with buprenorphine/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial. Am J Psychiatry. 2016;173:499–508.
   PubMed Web of Science ®Google Scholar
• FDA. Food and Drug Administration. Drugs@FDA (FDA approved drug products). Brexpiprazole. 2015 [cited 2016 Jun 8]. Available from:http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm].
   Google Scholar
• Citrome L, Stensbol TB, Maeda K. The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders? Expert Rev Neurother. 2015;15:1219–1229.
   PubMed Web of Science ®Google Scholar
• Gyertyan I, Kiss B, Saghy K, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59:925–935.
   PubMed Web of Science ®Google Scholar
• Durgam S, Earley W, Guo H, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016;77:371–378.
   PubMed Web of Science ®Google Scholar
• Allergan. Allergan and Richter Provide Update on Cariprazine Program 2016 [cited 2016 Dec 21]. Available from: http://www.allergan.com/investors/news/thomson-reuters/allergan-and-richter-provide-update-on-cariprazine].
   Google Scholar
• FDA. Food and Drug Administration. Drugs@FDA. Nuedexta. Drug approval package. 2010 [cited 2016 June 8]. Available from:http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021879Orig1s000TOC.cfm].
   Google Scholar
• EMA. European Medicines Agency. Nuedexta. Product Information. 2013 [cited 2016 June 8]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002560/human_med_1652.jsp&mid=WC0b01ac58001d124].
   Google Scholar
• Cummings JL, Lyketsos CG, Peskind ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with alzheimer disease dementia: a randomized clinical trial. Jama. 2015;314:1242–1254.
   PubMed Web of Science ®Google Scholar
• Avanir. Avanir pharmaceuticals announces initiation of phase III trial of AVP-786 for agitation in patients with Alzheimer’s Disease. 2015. Available from: http://www.avanir.com/press/avanir-pharmaceuticals-announces-initiation-phase-iii-trial-avp-786-agitation-patients].
   Google Scholar
• Garner R, Gopalakrishnan S, McCauley JA, et al. Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist. Pharmacol Res Perspect. 2015;3:e00198.
   PubMed Web of Science ®Google Scholar
• Ibrahim L, Diaz Granados N, Jolkovsky L, et al. A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol. 2012;32:551–557.
   PubMed Web of Science ®Google Scholar
• Paterson B, Fraser H, Wang C, et al. A Randomized, double-blind, placebo-controlled, sequential parallel study of CERC-301 in the adjunctive treatment of subjects with severe depression and recent active suicidal ideation despite antidepressant treatment. Presented at the 2015 National Network of Depression Centers Annual Conference, November-2015, Ann Arbor, MI, USA 2015;
   Google Scholar
• Salituro FG, Tomlinson RC, Baron BM, et al. Enzyme-activated antagonists of the strychnine-insensitive glycine/NMDA receptor. J Med Chem. 1994;37:334–336.
   PubMed Web of Science ®Google Scholar
• Zanos P, Piantadosi SC, Wu HQ, et al. The prodrug 4-Chlorokynurenine causes ketamine-like antidepressant Effects, but not side effects, by NMDA/GlycineB-Site inhibition. J Pharmacol Exp Ther. 2015;355:76–85.
   PubMed Web of Science ®Google Scholar
• Mealing GA, Lanthorn TH, Small DL, et al. Structural modifications to an N-methyl-D-aspartate receptor antagonist result in large differences in trapping block. J Pharmacol Exp Ther. 2001;297:906–914.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Smith MA, Pathak S, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry. 2014;19:978–985.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr., Mathews D, Ibrahim L, et al. A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry. 2013;74:257–264.
   PubMed Web of Science ®Google Scholar
• Moskal JR, Burgdorf JS, Stanton PK, et al. The Development of Rapastinel (Formerly GLYX-13); a rapid acting and long lasting antidepressant. Curr Neuropharmacol. 2016;15:47–56.
   Web of Science ®Google Scholar
• Preskorn S, Macaluso M, Mehra DO, et al. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract. 2015;21:140–149.
   PubMed Web of Science ®Google Scholar
• Javelot H. [Psychopharmacology of anxiety and depression: historical aspects, current treatments and perspectives]. Ann Pharm Fr. 2016;74:93–118.
   PubMedGoogle Scholar
• Roche. Pipeline summary. page 79 2015. Available from: http://www.roche.com/irp150128-annex.pdf].
   Google Scholar
• Lawrence J. The secret life of ketamine. Pharm J. 2015. Available from http://www.pharmaceutical-journal.com/news-and-analysis/features/the-secret-life-of-ketamine/20068151.article]
   Google Scholar
• Chocano-Bedoya PO, Mirzaei F, O’Reilly EJ, et al. C-reactive protein, interleukin-6, soluble tumor necrosis factor alpha receptor 2 and incident clinical depression. J Affect Disord. 2014;163:25–32.
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Fava M, Baer L, et al. Ziprasidone augmentation of escitalopram for major depressive disorder: efficacy results from a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2015;172:1251–1258.
   PubMed Web of Science ®Google Scholar
• Schmidt AW, Lebel LA, Howard HR Jr., et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425:197–201.
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004;65:217–221.
   PubMed Web of Science ®Google Scholar
• Halberstadt AL, Geyer MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology. 2011;61:364–381.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3:619–627.
   PubMed Web of Science ®Google Scholar
• Kircik LH. Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications. J Drugs Dermatol. 2010;9:1407–1411.
   PubMed Web of Science ®Google Scholar
• Husain MI, Chaudhry IB, Rahman RR, et al. Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial. Trials. 2015;16:410.
   PubMed Web of Science ®Google Scholar
• Miyaoka T, Wake R, Furuya M, et al. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37:222–226.
   PubMed Web of Science ®Google Scholar
• Dean OM, Maes M, Ashton M, et al. Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial. Clin Psychopharmacol Neurosci. 2014;12:180–188.
   PubMed Web of Science ®Google Scholar
• Venkiteshwaran A. Tocilizumab. MAbs. 2009;1:432–438.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Weinblatt ME, Sheng S, et al. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014;73:1616–1625.
   PubMed Web of Science ®Google Scholar
• Johnson&Johnson. Esketamine receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for major depressive disorder with imminent risk for suicide 2016 [cited 2016 June 8]. Available from: http://www.jnj.com/news/all/Esketamine-Receives-Breakthrough-Therapy-Designation-from-US-Food-and-Drug-Administration-for-Major-Depressive-Disorder-with-Imminent-Risk-for-Suicide].
   Google Scholar
• Kosten TR, Morgan C, Kosten TA. Depressive symptoms during buprenorphine treatment of opioid abusers. J Subst Abuse Treat. 1990;7:51–54.
   PubMed Web of Science ®Google Scholar
• Alkermes. Alkermes announces topline Results of FORWARD-3 and FORWARD-4, two phase 3 studies of ALKS 5461 in major depressive disorder 2016 [cited 2016 June 8th]. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-corporateNewsArticle&ID=2131031
   Google Scholar
• Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76:1232–1240.
   PubMed Web of Science ®Google Scholar
• Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76:1224–1231.
   PubMed Web of Science ®Google Scholar
• FDA. Food and Drug Administration. Drugs@FDA. Cariprazine. Label. 2015 [cited 2016 December 21st]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf].
   Google Scholar
• Burns JM, Boyer EW. Antitussives and substance abuse. Subst Abuse Rehabil. 2013;4:75–82.
   PubMedGoogle Scholar
• Nguyen L, Thomas KL, Lucke-Wold BP, et al. Dextromethorphan: an update on its utility for neurological and neuropsychiatric disorders. Pharmacol Ther. 2016;159:1–22.
   PubMed Web of Science ®Google Scholar
• Kulkarni SK, Dhir A. sigma-1 receptors in major depression and anxiety. Expert Rev Neurother. 2009;9:1021–1034.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Robson MJ, Healy JR, et al. Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan. Plos One. 2014;9:e89985.
   PubMed Web of Science ®Google Scholar
• Cerecor. CERC-301 2016 . [cited 2016 June 9]. Available from: http://www.cerecor.com/pipeline/cerc-301.php
   Google Scholar
• Bolshakov KV, Gmiro VE, Tikhonov DB, et al. Determinants of trapping block of N-methyl-d-aspartate receptor channels. J Neurochem. 2003;87:56–65.
   PubMed Web of Science ®Google Scholar
• AdisInsight. AZD 6765 2015 [cited 2016 May 27th]. Available from: http://adisinsight.springer.com/drugs/800026805].
   Google Scholar
• Allergan. Allergan’s rapastinel receives FDA breakthrough therapy designation for adjunctive treatment of major depressive disorder (MDD). 2016. Avaialble from: http://www.allergan.com/news/news/thomson-reuters/allergan-s-rapastinel-receives-fda-breakthrough-th].
   Google Scholar
• Park M, Niciu MJ, Zarate CA Jr. Novel glutamatergic treatments for severe mood disorders. Curr Behav Neurosci Rep. 2015;2:198–208.
   PubMedGoogle Scholar
• FDA. Food and Drug Administration. Drugs@FDA. Ziprasidone. Approval Package. 2009 [cited 2016 June 8]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020825Orig1s034.pdf].
   Google Scholar
• Shelton RC, Papakostas GI. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand. 2008;117:253–259.
   PubMed Web of Science ®Google Scholar
• Chandler GM, Iosifescu DV, Pollack MH, et al. RESEARCH: validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther. 2010;16:322–325.
   PubMed Web of Science ®Google Scholar
• Valkanova V, Ebmeier KP, Allan CL. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J Affect Disord. 2013;150:736–744.
   PubMed Web of Science ®Google Scholar
• Khandaker GM, Pearson RM, Zammit S, et al. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry. 2014;71:1121–1128.
   PubMed Web of Science ®Google Scholar
• van Dooren FE, Schram MT, Schalkwijk CG, et al. Associations of low grade inflammation and endothelial dysfunction with depression - The Maastricht Study. Brain Behav Immun. 2016;56:390–396.
   PubMed Web of Science ®Google Scholar
• Kohler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71:1381–1391.
   PubMed Web of Science ®Google Scholar
• Penn E, Tracy DK. The drugs don’t work? antidepressants and the current and future pharmacological management of depression. Ther Adv Psychopharmacol. 2012;2:179–188.
   PubMedGoogle Scholar
• Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of patients with major depressive disorder. Am Psychiatr Assoc. 2010; APA Guidelines:1–151. [cited 2016 Dec 21]. Available from: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
   Google Scholar
• Saba G, Nieto I, Bation R, et al. [Other therapeutic strategies]. Presse Med. 2016;45:323–332.
   PubMed Web of Science ®Google Scholar
• Guzman F. Differences between tricyclic antidepressants and SNRIs mechanism of action. Pharmacol Corner. 2016. [cited 2016 June 17]. Available from: http://pharmacologycorner.com/differences-between-tricyclic-antidepressants-and-selective-serotonin-norepinephrine-reuptake-inhibitors-mechanism-of-action/
   Google Scholar
• Trindade E, Menon D, Topfer LA, et al. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Cmaj. 1998;159:1245–1252.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–1917.
   PubMed Web of Science ®Google Scholar
• Borges S, Chen YF, Laughren TP, et al. Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug Administration. J Clin Psychiatry. 2014;75:205–214.
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Baumann J, Wheeler-Castillo C, et al. The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. Pharmaceuticals. 2010;3:19–41.
   Google Scholar
• El-Hage W. [Roadmap for therapeutic strategies of treatment resistant depression]. Presse Med. 2016;45:320–322.
   PubMed Web of Science ®Google Scholar
• Thase ME, Rush AJ. When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;53(Suppl. 13):23–29.
   Google Scholar
• Hassan AK, Farmer KC, Brahm NC, et al. Evaluating antidepressant treatment prior to adding second-line therapies among patients with treatment-resistant depression. Int J Clin Pharm. 2016;38:429–437.
   PubMed Web of Science ®Google Scholar
• Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74:250–256.
   PubMed Web of Science ®Google Scholar
• Pittenger C, Sanacora G, Krystal JH. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets. 2007;6:101–115.
   PubMedGoogle Scholar
• Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62:63–77.
   PubMed Web of Science ®Google Scholar
• Duman RS. Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections. Dialogues Clin Neurosci. 2014;16:11–27.
   PubMed Web of Science ®Google Scholar
• Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959–964.
   PubMed Web of Science ®Google Scholar
• Freedman R. Further Investigation of Ketamine. Am J Psychiatry. 2016;173:761–762.
   PubMed Web of Science ®Google Scholar
• Ray WA, Chung CP, Murray KT, et al. Prescription of long-acting opioids and mortality in patients with chronic noncancer pain. JAMA. 2016;315:2415–2423.
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–962.
   PubMed Web of Science ®Google Scholar
• Citrome L. Drug safety evaluation of ziprasidone. Expert Opin Drug Saf. 2011;10:437–448.
   PubMed Web of Science ®Google Scholar
• Tian G, Mi J, Wei X, et al. Circulating interleukin-6 and cancer: a meta-analysis using Mendelian randomization. Sci Rep. 2015;5:11394.
   PubMed Web of Science ®Google Scholar
• Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):10–17.
   PubMedGoogle Scholar
• Lam RW, Milev R, Rotzinger S, et al. Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. BMC Psychiatry. 2016;16:105.
   PubMed Web of Science ®Google Scholar
• Judd LL, Schettler PJ, Solomon DA, et al. Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. J Affect Disord. 2008;108:49–58.
   PubMed Web of Science ®Google Scholar
• Lam RW, Parikh SV, Michalak EE, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. Ann Clin Psychiatry. 2015;27:142–149.
   PubMed Web of Science ®Google Scholar